AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6996816
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg BID cephradine
Trial: 30628167
Drug: Virgin olive
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virgin olive oil (10 g d-1)
Trial: 30628167
Drug: Whole grain
RxNorm normalized name: Whole grain barley
DrugBank: Barley (DB10506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole grain (25 g d-1)
Trial: 30628167
Drug: Nuts (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nuts (30 g d-1)
Trial: 30628167
Drug: Legumes (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Legumes (25 g d-1)
Trial: 30628167
Drug: Fish (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish (25 g d-1)
Trial: 27216350
Drug: oxymetazoline plus
RxNorm normalized name: oxymetazoline Nasal Spray [Duramist Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxymetazoline plus mometasone furoate nasal spray (MFNS)
Trial: 27216350
Drug: placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo plus mometasone furoate nasal spray (MFNS)
Trial: 17083910
Drug: 350 mm²
RxNorm normalized name: allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350 mm² Baerveldt glaucoma implant
Trial: 7615107
Drug: Finasteride 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride 7.5 mg/d for 9 months
Trial: 264923
Drug: Two fluoride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two fluoride tablets daily
Trial: 264923
Drug: One fluoride
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One fluoride tablet daily
Trial: 264923
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet (control group)
Trial: 25632742
Drug: Aripiprazole (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (5 mg, once daily)
Trial: 20206777
Drug: Vaginal brachytherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal brachytherapy (VBT) 21 Gy high-dose rate in three fractions or 30 Gy low-dose rate
Trial: 3407609
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg beta-carotene
Trial: 2378704
Drug: Pressure applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure applied after injection of heparin
Trial: 2378704
Drug: Aspiration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspiration of the syringe prior to injecting heparin
Trial: 2378704
Drug: Subsequent injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent injections with pressure applied after injection
Trial: 27025688
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy to the quadriceps
Trial: 19052401
Drug: Evening primrose
RxNorm normalized name: EVENING PRIMROSE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening primrose oil (EPO) 500 mg capsules
Trial: 19052401
Drug: Placebo (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (300 mg sunflower oil capsules)
Trial: 9184611
Drug: Nefazodone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone (200 mg/day for Days 1-7; 400 mg/day for Days 8-56)
Trial: 9184611
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg/day for Days 1-56)
Trial: 9184611
Drug: Both Nefazodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both Nefazodone and Fluoxetine
Trial: 3513528
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg guanfacine
Trial: 3513528
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg guanfacine
Trial: 12854359
Drug: Furosemide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (40 mg tablet)
Trial: 29219935
Drug: Intrathecal bupivacaine/morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine/morphine (12.5 mg/300 μg)
Trial: 29219935
Drug: Sham procedure
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sham procedure and bolus of piritramide (0.1 mg/kg)
Trial: 26962830
Drug: G(120-0) ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G(120-0) ≥ 2.50 mmol/L or G30 ≥ 9.75 mmol/L
Trial: 26962830
Drug: High G(120-0)
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High G(120-0) and high G30
Trial: 22621162
Drug: Peak SE
RxNorm normalized name: selenomethionine Se 75
DrugBank: Selenomethionine Se-75 (DB09400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peak SE self‐etch bonding agent
Trial: 22621162
Drug: Peak LC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peak LC etch‐and‐rinse bonding agent
Trial: 15883748
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (500 mg, bd, 14 days)
Trial: 10442299
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate 200 mg i.m. every 2 weeks
Trial: 1333518
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (cyclophosphamide 400 mg/m2, doxorubicin 40 mg/m2, and cisplatin 40 mg/m2 for six cycles)
Trial: 1333518
Drug: No active
RxNorm normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active treatment (control group)
Trial: 1333518
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (CAP)
Trial: 4001254
Drug: Social-learning-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social-learning-based treatment
Trial: 31509295
Drug: Alpine climate
RxNorm normalized name: Alpine strawberry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpine climate treatment
Trial: 31509295
Drug: Moderate maritime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate maritime climate treatment
Trial: 24889392
Drug: L-ornithine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-ornithine (400 mg/day)
Trial: 15982429
Drug: Kinetic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinetic therapy (PediDyne bed)
Trial: 15982429
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (manual turning and percussion)
Trial: 15982429
Drug: Kinetic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinetic therapy after standard therapy
Trial: 12009344
Drug: Desogestrel (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desogestrel (0.15 mg) plus Ethinyl Estradiol (0.030 mg) daily for 21 days followed by a 7-day rest for 12 months
Trial: 12009344
Drug: Cyproterone Acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone Acetate (2 mg) plus Ethinyl Estradiol (0.035 mg) daily for 21 days followed by a 7-day rest for 12 months
Trial: 9629401
Drug: Propranolol 60
RxNorm normalized name: propranolol 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 60 mg/day plus Flunarizine 10 mg/day
Trial: 9629401
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (Propranolol, Flunarizine, Both)
Trial: 8198246
Drug: Ophthalmic sodium
RxNorm normalized name: fluorescein ophthalmic sodium compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic sodium cromoglycate 2% four times daily
Trial: 8198246
Drug: Ophthalmic sodium
RxNorm normalized name: fluorescein ophthalmic sodium compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic sodium cromoglycate 4% twice daily
Trial: 8198246
Drug: Placebo eye-drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo eye-drops twice daily
Trial: 8383058
Drug: Propranolol 80
RxNorm normalized name: propranolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 80 mg x 2
Trial: 2454378
Drug: Carvedilol (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (both doses)
Trial: 29090475
Drug: Intense method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intense method for plaque control - daily powered tooth brushing with 1% Chlorhexidine gel
Trial: 29090475
Drug: Conventional method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional method for plaque control - daily manual tooth brushing with a standardised commercial toothpaste
Trial: 19941334
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of muscle ache and cramps
Trial: 12853344
Drug: VAD bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAD bolus (vincristine 0.4 mg i.v., doxorubicin 9 mg/m² i.v., dexamethasone 40 mg p.o. daily for 4 days)
Trial: 12853344
Drug: VAD doxil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAD doxil (vincristine 2 mg i.v., liposomal doxorubicin 40 mg/m² i.v. on day 1, dexamethasone 40 mg p.o. daily for 4 days)
Trial: 25480673
Drug: Shenyankangfu tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenyankangfu tablets
Trial: 25480673
Drug: losartan potassium
RxNorm normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: losartan potassium 50 mg
Trial: 25480673
Drug: losartan potassium
RxNorm normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: losartan potassium 100 mg
Trial: 25480673
Drug: Shenyankangfu tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenyankangfu tablets + losartan potassium 50 mg
Trial: 25480673
Drug: Shenyankangfu tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenyankangfu tablets + losartan potassium 100 mg
Trial: 17715211
Drug: VML-670 (5-HT(1A)
RxNorm normalized name: 5-HT
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VML-670 (5-HT(1A) and 5-HT(1D) agonist)
Trial: 12528088
Drug: Carvedilol (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (37.5 +/- 13.5 mg/12 h)
Trial: 12528088
Drug: Bisoprolol (5.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (5.4 +/- 3.0 mg/d)
Trial: 7537286
Drug: Risperidone 6
RxNorm normalized name: risperidone 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 6 to 16 mg/day
Trial: 45068
Drug: Oxytocin induced
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin induced labor using amniotomy and oxytocin infusion with the Cardiff Infusion System Mark II
Trial: 28081548
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of bevacizumab with second-line chemotherapy
Trial: 21394500
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (ZOL) 4 mg administered intravenously after each chemotherapy cycle for 60 months post-randomisation (six doses in the first 6 months, eight doses in the following 24 months and five doses in the final 30 months).
Trial: 21394500
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received neither additional treatment nor intravenous ZOL.
Trial: 14994569
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric oxide inhalation (Group A)
Trial: 14994569
Drug: No nitric
RxNorm normalized name: Nitric Acid
DrugBank: Nitric acid (DB15995)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No nitric oxide inhalation (Group B)
Trial: 10978060
Drug: Hypothermic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothermic treatment using the 'forced air' method for 6 hours (cooling blanket with a flow of cool air at 10 degrees C)
Trial: 10978060
Drug: Hypothermic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothermic treatment
Trial: 1739570
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at doses of 1.2, 1.4, 1.6, 1.8, 2.0, 2.2, 2.4, and 2.6 mg kg‐1
Trial: 23360359
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (CoQ10) 200 mg/d for 8 weeks
Trial: 16540798
Drug: Higher-LCPUFA formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-LCPUFA formula with 17 mg DHA, 34 mg ARA, 85 mg ALA, and 860 mg LA per 100 kcal
Trial: 16540798
Drug: Lower-LCPUFA formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-LCPUFA formula with 8 mg DHA, 21 mg ARA, 110 mg ALA, and 1,000 mg LA per 100 kcal
Trial: 1591828
Drug: tissue-type plasminogen
RxNorm normalized name: Tissue-type plasminogen activator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tissue-type plasminogen activator (100 mg over 2 hours)
Trial: 3901674
Drug: Antidepressant medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medication plus cognitive therapy
Trial: 30453332
Drug: Short-term intensive
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term intensive (STI) therapy
Trial: 30646152
Drug: Trial control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial control strategy (increased cholesterol level monitoring and use of electronic pill bottles)
Trial: 22129562
Drug: Antidepressant medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medication combinations (mirtazapine and venlafaxine)
Trial: 20012484
Drug: Lubiprostone 24
RxNorm normalized name: LUBIPROSTONE 24MCG CAP,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubiprostone 24 mcg twice daily
Trial: 18843432
Drug: Resistance training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance training combined with coenzyme Q10 supplementation (200 mg/day)
Trial: 26872008
Drug: Irinotecan 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 125 mg/m2 and cisplatin 60 mg/m2 (high-dose group)
Trial: 26872008
Drug: Irinotecan 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 80 mg/m2 and cisplatin 50 mg/m2 (low-dose group)
Trial: 26872008
Drug: Both high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both high-dose and low-dose groups
Trial: 23338668
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium 4 % spray gel applied two or three times daily for 3 days
Trial: 17324628
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of carbohydrates per day
Trial: 17324628
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of carbohydrates per day
Trial: 12137830
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (urethrocystoscopy)
Trial: 8578801
Drug: SPf(66)n synthetic
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPf(66)n synthetic malaria vaccine
Trial: 31164156
Drug: Monthly income
RxNorm normalized name: Lincomed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly income 1001-2000 Ethiopian birr
Trial: 31164156
Drug: Monthly income
RxNorm normalized name: Lincomed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly income 2001-3000 Ethiopian birr
Trial: 25561337
Drug: Isavuconazole 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isavuconazole 200 mg on day 1 and then 50 mg once daily (arm A)
Trial: 25561337
Drug: Isavuconazole 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isavuconazole 400 mg on day 1 and then 400 mg once-weekly (arm B)
Trial: 25561337
Drug: Isavuconazole 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isavuconazole 400 mg on day 1 and then 100 mg once daily (arm C)
Trial: 25561337
Drug: Fluconazole 200
RxNorm normalized name: fluconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 200 mg on day 1 and then 100 mg once daily (arm D)
Trial: 21876476
Drug: cinacalcet (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cinacalcet (30 mg daily)
Trial: 19706990
Drug: Exenatide QW
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide QW 0.8 mg
Trial: 19706990
Drug: Exenatide QW
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide QW 2.0 mg
Trial: 9756250
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g hydrolyzed guar fiber
Trial: 7923804
Drug: Alpha-interferon (Alfaferone:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-interferon (Alfaferone: Alfa-Wassermann Bologna, Italy) 3 x 10(6) IU by i.m. injection every other day for four weeks (total of 12 injections)
Trial: 31557450
Drug: DXM+ (Dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DXM+ (Dexmedetomidine infusion at 4 μg/kg/hr)
Trial: 28800383
Drug: GSK2793660 (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2793660 (12 mg once daily for 21 days)
Trial: 28800383
Drug: GSK2793660 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2793660 (single escalating doses from 0.5 to 20 mg)
Trial: 23364629
Drug: Oral paricalcitol
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral paricalcitol treatment at doses of 1 mcg/day
Trial: 23364629
Drug: 1 ampoule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ampoule calcifediol/wk (0.266 mg/wk=16 000U) orally
Trial: 19490137
Drug: Group II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II: verbal instructions and a self-educational manual on oral hygiene without illustrations
Trial: 19490137
Drug: Group III:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group III: oral hygiene guidance with verbal instructions and a self-teaching manual
Trial: 19490137
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group I: continued personal oral hygiene routine
Trial: 17046166
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg oral micronized progesterone
Trial: 15301325
Drug: Intensive glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glucose management protocol (continuous intravenous insulin if glucose >200 mg/dL, target glucose <140 mg/dL)
Trial: 9152646
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of troponin T and exercise test response (Low risk n = 84)
Trial: 9152646
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of troponin T and exercise test response (Intermediate risk n = 406)
Trial: 9152646
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of troponin T and exercise test response (High risk n = 276)
Trial: 8490912
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin 750 mg plus clindamycin 600 mg every 8 hours
Trial: 8490912
Drug: IV aztreonam
RxNorm normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV aztreonam 2 g plus clindamycin 600 mg every 8 hours
Trial: 8490912
Drug: Oral regimen
RxNorm normalized name: aspirin Oral Tablet [Anacin Aspirin Regimen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral regimen
Trial: 3124734
Drug: Ceftazidime 2
RxNorm normalized name: ceftazidime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 2 g intravenously every 12 hours
Trial: 27316224
Drug: Intranasal sodium
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal sodium citrate solution
Trial: 27316224
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride solution (placebo control)
Trial: 25195371
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose Qianlongtong Capsule (6 capsules once, tid for 7 days)
Trial: 25195371
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose Qianlongtong Capsule (3 capsules once, tid for 7 days)